19254918

Source:http://linkedlifedata.com/resource/pubmed/id/19254918

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists.
Subject	Predicate	Object	Context
pubmed-article:19254918	rdf:type	pubmed:Citation	lld:pubmed
pubmed-article:19254918	lifeskim:mentions	umls-concept:C0030705	lld:lifeskim
pubmed-article:19254918	lifeskim:mentions	umls-concept:C0038013	lld:lifeskim
pubmed-article:19254918	lifeskim:mentions	umls-concept:C0037935	lld:lifeskim
pubmed-article:19254918	lifeskim:mentions	umls-concept:C1122087	lld:lifeskim
pubmed-article:19254918	lifeskim:mentions	umls-concept:C1522326	lld:lifeskim
pubmed-article:19254918	lifeskim:mentions	umls-concept:C1704419	lld:lifeskim
pubmed-article:19254918	lifeskim:mentions	umls-concept:C0205179	lld:lifeskim
pubmed-article:19254918	pubmed:issue	5	lld:pubmed
pubmed-article:19254918	pubmed:dateCreated	2009-4-17	lld:pubmed
pubmed-article:19254918	pubmed:abstractText	To evaluate the effectiveness and safety of adalimumab in treating patients with AS and advanced structural damage.	lld:pubmed
pubmed-article:19254918	pubmed:language	eng	lld:pubmed
pubmed-article:19254918	pubmed:journal	http://linkedlifedata.com/r...	lld:pubmed
pubmed-article:19254918	pubmed:citationSubset	AIM	lld:pubmed
pubmed-article:19254918	pubmed:chemical	http://linkedlifedata.com/r...	lld:pubmed
pubmed-article:19254918	pubmed:chemical	http://linkedlifedata.com/r...	lld:pubmed
pubmed-article:19254918	pubmed:chemical	http://linkedlifedata.com/r...	lld:pubmed
pubmed-article:19254918	pubmed:chemical	http://linkedlifedata.com/r...	lld:pubmed
pubmed-article:19254918	pubmed:chemical	http://linkedlifedata.com/r...	lld:pubmed
pubmed-article:19254918	pubmed:status	MEDLINE	lld:pubmed
pubmed-article:19254918	pubmed:month	May	lld:pubmed
pubmed-article:19254918	pubmed:issn	1462-0332	lld:pubmed
pubmed-article:19254918	pubmed:author	pubmed-author:KronMartinaM	lld:pubmed
pubmed-article:19254918	pubmed:author	pubmed-author:RudwaleitMart...	lld:pubmed
pubmed-article:19254918	pubmed:author	pubmed-author:OlivieriIgnaz...	lld:pubmed
pubmed-article:19254918	pubmed:author	pubmed-author:BokiKyriaki...	lld:pubmed
pubmed-article:19254918	pubmed:author	pubmed-author:KupperHartmut...	lld:pubmed
pubmed-article:19254918	pubmed:author	pubmed-author:JärvinenPentt...	lld:pubmed
pubmed-article:19254918	pubmed:author	pubmed-author:KarySonjaS	lld:pubmed
pubmed-article:19254918	pubmed:author	pubmed-author:WongRobert...	lld:pubmed
pubmed-article:19254918	pubmed:author	pubmed-author:GriepEduard...	lld:pubmed
pubmed-article:19254918	pubmed:issnType	Electronic	lld:pubmed
pubmed-article:19254918	pubmed:volume	48	lld:pubmed
pubmed-article:19254918	pubmed:owner	NLM	lld:pubmed
pubmed-article:19254918	pubmed:authorsComplete	Y	lld:pubmed
pubmed-article:19254918	pubmed:pagination	551-7	lld:pubmed
pubmed-article:19254918	pubmed:dateRevised	2011-11-17	lld:pubmed
pubmed-article:19254918	pubmed:meshHeading	pubmed-meshheading:19254918...	lld:pubmed
pubmed-article:19254918	pubmed:meshHeading	pubmed-meshheading:19254918...	lld:pubmed
pubmed-article:19254918	pubmed:meshHeading	pubmed-meshheading:19254918...	lld:pubmed
pubmed-article:19254918	pubmed:meshHeading	pubmed-meshheading:19254918...	lld:pubmed
pubmed-article:19254918	pubmed:meshHeading	pubmed-meshheading:19254918...	lld:pubmed
pubmed-article:19254918	pubmed:meshHeading	pubmed-meshheading:19254918...	lld:pubmed
pubmed-article:19254918	pubmed:meshHeading	pubmed-meshheading:19254918...	lld:pubmed
pubmed-article:19254918	pubmed:meshHeading	pubmed-meshheading:19254918...	lld:pubmed
pubmed-article:19254918	pubmed:meshHeading	pubmed-meshheading:19254918...	lld:pubmed
pubmed-article:19254918	pubmed:meshHeading	pubmed-meshheading:19254918...	lld:pubmed
pubmed-article:19254918	pubmed:meshHeading	pubmed-meshheading:19254918...	lld:pubmed
pubmed-article:19254918	pubmed:meshHeading	pubmed-meshheading:19254918...	lld:pubmed
pubmed-article:19254918	pubmed:meshHeading	pubmed-meshheading:19254918...	lld:pubmed
pubmed-article:19254918	pubmed:meshHeading	pubmed-meshheading:19254918...	lld:pubmed
pubmed-article:19254918	pubmed:year	2009	lld:pubmed
pubmed-article:19254918	pubmed:articleTitle	Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion.	lld:pubmed
pubmed-article:19254918	pubmed:affiliation	Medical Department I, Rheumatology, Charité, Campus Benjamin Franklin Hospital, Berlin, Germany. martin.rudwaleit@charite.de	lld:pubmed
pubmed-article:19254918	pubmed:publicationType	Journal Article	lld:pubmed
pubmed-article:19254918	pubmed:publicationType	Clinical Trial	lld:pubmed
pubmed-article:19254918	pubmed:publicationType	Research Support, Non-U.S. Gov't	lld:pubmed
pubmed-article:19254918	pubmed:publicationType	Multicenter Study	lld:pubmed
http://linkedlifedata.com/r...	pubmed:referesTo	pubmed-article:19254918	lld:pubmed